Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186

The DOI matches its Crossref record.

Prognostic Value of O-(2-18F-Fluoroethyl)-L-Tyrosine PET and MRI in Low-Grade Glioma

Open access
Floeth, F. W., Pauleit, D., Sabel, M., Stoffels, G., Reifenberger, G., Riemenschneider, M. J., Jansen, P., Coenen, H. H., Steiger, H.-J., Langen, K.-J. · 2007 · Journal of Nuclear Medicine

Abstract

UNLABELLED: In glioma of World Health Organization (WHO) grade II (low-grade glioma), the natural course of a particular patient is not predictable and the treatment strategy is controversial. We determined prognostic factors in adult patients with untreated, nonenhancing, supratentorial low-grade glioma with special regard to PET using the amino acid O-(2-(18)F-fluoroethyl)-L-tyrosine ((18)F-FET) and MRI. METHODS: In a prospective study, baseline (18)F-FET PET and MRI analyses were performed on 33 consecutive patients with histologically confirmed low-grade glioma. None of the patients had radiation or chemotherapy. Clinical, histologic, therapeutic (initial cytoreduction vs. biopsy), (18)F-FET uptake, and MRI morphologic parameters were analyzed for their prognostic significance. Statistical endpoints were clinical or radiologic tumor progression, malignant transformation to glioma of WHO grade III or IV (high-grade glioma), and death. RESULTS: Baseline (18)F-FET uptake and a diffuse versus circumscribed tumor pattern on MRI were highly significant predictors of prognosis (P < 0.01). By the combination of these prognostically significant variables, 3 major prognostic subgroups of low-grade glioma patients could be identified. The first of these subgroups was patients with circumscribed low-grade glioma on MRI without (18)F-FET uptake (n = 11 patients, progression in 18%, no malignant transformation and no death). The second subgroup was patients with circumscribed low-grade glioma with (18)F-FET uptake (n = 13 patients, progression in 46%, malignant transformation to a high-grade glioma in 15%, and death in 8%). The third subgroup was patients with diffuse low-grade glioma with (18)F-FET uptake (n = 9 patients, progression in 100%, malignant transformation to a high-grade glioma in 78%, and death in 56%). CONCLUSION: We conclude that baseline amino acid uptake on (18)F-FET PET and a diffuse versus circumscribed tumor pattern on MRI are strong predictors for the outcome of patients with low-grade glioma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2967/jnumed.106.037895

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 186

Metadata

Authors
Floeth, F. W., Pauleit, D., Sabel, M., Stoffels, G., Reifenberger, G., Riemenschneider, M. J., Jansen, P., Coenen, H. H., Steiger, H.-J., & Langen, K.-J.
Venue
Journal of Nuclear Medicine
Published
2007-04-01
Volume
48
Issue
4
Pages
519-527
ISSN
0161-5505 (ISSN-L)
OpenAlex
W1975839853
Cited by
186
References
0
FWCI
4.94
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic Value of O-(2-18F-Fluoroethyl)-L-Tyrosine PET and MRI in Low-Grade Glioma. https://app.cochat.ai/papers/10.2967/jnumed.106.037895
The paper
Floeth, F. W., Pauleit, D., Sabel, M., Stoffels, G., Reifenberger, G., Riemenschneider, M. J., Jansen, P., Coenen, H. H., Steiger, H.-J., & Langen, K.-J. (2007). Prognostic Value of O-(2-18F-Fluoroethyl)-L-Tyrosine PET and MRI in Low-Grade Glioma. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.106.037895

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.